Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of Inflammatory Markers in Hemodialysis Patients

Phase 4

• Conditions: End Stage Renal Disease.; Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease; I13.11

• Registration Number: IRCT20200724048193N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with ESRD
Indication of treatment with phosphate binders
Hemodialysis preformation for more than three months

Exclusion Criteria

Impossibility of alternative treatment with Sevelamer Hydrochloride or Calcium Carbonate
Cigarette, alcohol and drug abuse
History of immunological diseases
Any type of cancer
Recent active infection
Previous kidney transplant history
History of receiving immunosuppressive treatment

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Endotoxin. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.;Soluable CD-14. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.

Secondary Outcome Measures

Name	Time	Method
Possible side effects. Timepoint: Two months after starting treatment. Method of measurement: Assessment and questioning of the patient.